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                                              Abstract 
      In the present study an inactivated IBD vaccine were developed 
from a local field isolate of the virus. It is anticipated that the field 
virus would induce better immune response in vaccinated birds due 
to its close antigenic relation ship. A field outbreak of the disease 
that occurred in 2006 in Khartoum state (Shambat) was investigated 
that caused 70% mortality even in vaccinated bird. IBDV was 
detected by AGID test, isolation in cell culture (CEF) and 
reproduction of the disease in experimental chicks. The virus was 
isolated in CEF cell culture and identified serologically by AGDT. 
The virus was designed Shambat/06 and further propagated for two 
passages in cell culture and the TCID50was determined. Then the 
CEF cell culture harvest was inactivated using formalin and the 
viruse inactivation was tested used experimental chicks. 
      A total of 140 layer chicks were used to determine the efficancy   
and safety of the developed vaccine and to compare it with 
commercial IBDV vaccines D78, Bur706.  
           The results showed that when the bursa suspension was 
inoculated onto chick embryo fibroblast cell culture it induce clear 
cytopathic effects after 5 days of inoculation. Clinical signs observed 
after experimental infection of susceptible   chicks were similar to the 
classical IBD clinical signs and were characterized by sudden onset 
of depression, dullness, ruffled featherand death. Tissues collected 
from experimental chickens were examined histopathologically. 
Bursal of fabricius showed hemorrhage in the connective tissues and 
 xi
the dissociated follicular cells beside edema in the follicle and 
degeneration of follicles. A volume of 100 ml of the inactivated virus 
was mixed with Aluminum hydroxide as adjuvant. Experimental 
chicks were vaccinated by the inactivated vaccine and for comparison 
additional chicks were vaccinated with D78and Bur706 commercial 
IBD vaccines. No signs or lesions of IBD were seen and vaccinated 
chicks remained healthy throughout the experiment, which means that 
the IBDV in the vaccine was completely inactivated by the formalin.  
           Two preparations were made for the vaccine, with and without 
Aluminum hydroxide adjuvant and two routes of vaccination; 
intramuscular (I/M) and subcutaneous (S/C) were tried. The best 
result in terms of immune response and withstanding challenge was 
obtained when the adjuvanted inactivated vaccine was given by the 
intramuscular route. Results showed also that the developed vaccine 
without adjuvant when given by I/M gave a relatively lower 
protective immune response of 73.3% comparing with 93.3% for the 
adjuvanted vaccine which mean that the absent of the adjuvant make 
loss of 20% at immune response. 
      The results also revealed comparable protective immune 
response between D78, Bur706 vaccines and the developed 
adjuvanted vaccine when the latter was given by I/M route. On the 
other hand, the developed vaccine without adjuvant showed 20% 
lower protective immune response compared with the commercial 
vaccines. The results also showed similler withstanding challenge for 
both shambat/06/adj and D78 while Bur706 was slightly better than 
both above vaccines. The higher uniformed higher titer from 8,000 
 xii
upto 12,000 was induced in vaccinated chicks by the developed 
vaccine with adjuvant when given by I/M.   
  The efficacy of the developed vaccine observed in the present study 
is promising and indicate that the developed vaccine may became a 
good alternative method to control IBD in Sudan. 
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  وﺣﺔﻣﻠﺨـﺺ اﻷﻃﺮ
ﻓﻲ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺘﻡ ﺍﻫﻤﺎﺩ ﺍﻟﻔﻴﺭﻭﺱ ﺍﻟﻤﺴﺒﺏ ﻟﻤﺭﺽ ﺍﻟﻘﻤﺒﻭﺭﺓ ﻤﻥ ﻋﺘﺭﻩ  ﻤﺤﻠﻴﺔ، ﻭﺍﻟﺘﻲ ﻤﻥ 
ﻡ ﺘﻡ ﺭﺼﺩ 6002ﻓﻲ ﺍﻟﻌﺎﻡ . ﺍﻟﻤﺘﻭﻗﻊ ﺍﻥ ﺘﻌﻁﻲ ﻤﻨﺎﻋﺔ ﻋﺎﻟﻴﺔ ﻨﺘﻴﺠﺔ ﺃﻟﻲ ﺍﻟﺘﻘﺎﺭﺏ ﺍﻻﻨﺘﺠﻴﻨﻲ 
ﺍﻨﺘﺸﺎﺭ ﻭﺒﺎﺌﻲ ﻟﻠﻤﺭﺽ ﻭﻤﻥ ﺨﻼل ﻤﺭﺍﺠﻌﺔ ﺍﻟﺤﻅﺎﺌﺭ ﻟﻭﺤﻅ ﺁﻥ ﻤﻌﺩل ﺍﻟﻤﻭﺕ ﻴـﺼل  ﺃﻟـﻲ 
ﻌﺽ ﺍﻟﺤﺎﻻﺕ ﻋﻠﻲ ﺍﻟﺭﻏﻡ ﻤﻥ ﺃﻨﻬﺎ ﺘﻡ ﺘﻁﻌﻴﻤﻬﺎ ﺒﻠﻘﺎﺡ ﻤﺭﺽ ﺠﺭﺍﺏ ﻓﺎﺒﺭﻴﺸﺹ ﻓﻲ ﺒ % 07
  . ﺍﻟﻤﻌﺩﻱ  
ﺘﻡ ﺍﺨﺫ ﻋﻴﻨﺎﺕ ﺒﺎﻟﺘﺎﺭﻴﺦ ﺍﻟﺴﺎﺒﻕ ﻤﻥ ﺤﻅﻴﺭﺓ ﻟﻠﺩﻭﺍﺠﻥ ﺒﺸﻤﺒﺎﺕ، ﻭﺘﻡ ﺍﻟﺘﻌﺭﻑ ﻋﻠﻲ ﻓﻴـﺭﻭﺱ 
ﻭﻋـﻥ . ﺍﻟﻘﻤﺒﻭﺭﻩ ﺍﻟﻤﺴﺒﺏ ﻟﻠﻤﺭﺽ ﻋﻥ ﻁﺭﻴﻘﺔ ﺍﺨﺘﺒﺎﺭ ﺍﻟﺘﺭﺴﻴﺏ ﺍﻟﻤﻨﺎﻋﻲ ﻓﻲ ﺍﺠﺎﺭ ﺍﻟﺠـل 
  .ﻨﺎﺕ ﺘﺠﺎﺭﺏ ﻁﺭﻴﻕ ﺍﻟﺯﺭﻉ  ﺍﻟﺨﻠﻭﻱ  ﻭﺒﺎﺴﺘﺨﺩﺍﻡ ﺤﻴﻭﺍ
ﺜﻡ ﻋﺯل ﺍﻟﻔﻴﺭﻭﺱ ﻓﻲ ﺍﻟﺯﺭﻉ ﺍﻟﺨﻠﻭﻱ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺨﻼﻴﺎ ﺠﻨﻴﻥ ﺒﻴﺽ ﺍﻟﺩﻭﺍﺠﻥ ﺘﻡ ﺘﻌﺭﻴﻔـﻪ ﺁﻭ 
ﻭﺒﻌﺩ ﺘﻤﺭﻴﺭﻩ ﻓﻲ ﺨﻼﻴﺎ ﺠﻨﻴﻥ ﺍﻟﺒﻴﺽ ﺍﻟﻨﺎﻤﻲ ﻟﻤﺭﺘﻴﻥ ﺘﻡ ﺤﺴﺎﺏ ( ﺸﻤﺒﺎﺕ / 60)ﺘﺴﻤﻴﺘﻪ ﺒﻲ 
ﺍﻟﻭﺤﺩﺍﺕ ﺍﻟﻤﻌﺩﻴﺔ ﻓﻲ ﺍﻟﺯﺭﻉ ﺍﻟﺨﻠﻭﻱ ، ﺒﻌﺩ ﺫﻟﻙ ﺘﻡ ﺤﺼﺎﺩ ﺍﻟﻔﻴﺭﻭﺱ ﻭﺍﻫﻤـﺎﺩﻩ ﺒﺎﺴـﺘﻌﻤﺎل 
  . ﻥ ﺍﺨﺘﺒﺎﺭ ﻟﻠﺘﺄﻜﺩ ﻤﻥ ﺍﻜﺘﻤﺎل ﺍﻫﻤﺎﺩ ﺍﻟﻔﻴﺭﻭﺱ ﺍﻟﻔﻭﺭﻤﺎﻟﻴﻥ ﻭﺍﺠﺭﻴ
 ﻜﺘﻜﻭﺕ ﺒﻴﺎﺽ  ﻭﺫﻟﻙ ﻟﻘﻴﺎﺱ ﻗﻭﻩ ﻭﺴﻼﻤﺔ ﺍﻟﻔﺎﻜﺴﻴﻥ ﺍﻟﻤﺤـﻀﺭ 041ﻟﻬﺫﻩ ﺍﻟﺘﺠﺭﺒﺔ ﺘﻡ ﺠﻠﺏ 
   .   87 D , 607 ruBﻤﻌﻤﻠﻴﺎ ﻭﻤﻥ ﺜﻡ ﻤﻘﺎﺭﻨﺘﻪ ﻤﻊ ﺍﻟﻔﺎﻜﺴﻴﻨﺎﺕ ﺍﻟﺘﺠﺎﺭﻴﺔ 
ﺍﻟﻨﺘﺎﺌﺞ ﺃﻭﻀﺤﺕ ﺍﻨﻪ ﻋﻥ ﺤﻘﻥ ﻤﻌﻠﻕ ﺠﺭﺍﺏ ﻓﺎﺒﺭﻴﺸﺹ ﻋﻠﻲ ﺨﻼﻴﺎ ﺠﻨﻴﻥ ﺍﻟﺒـﻴﺽ ﺍﻟﻨـﺎﻤﻲ 
 ﺃﻴـﺎﻡ 5ﻤﺯﺭﻭﻉ ﺨﻠﻭﻴﺎ ﻓﺎﻨﻪ ﻴﻅﻬﺭ ﺍﺜﺭ ﻤﺭﻀﻲ ﻋﻠﻲ ﺍﻟﺨﻼﻴﺎ ﺒﺼﻭﺭﺓ ﻭﺍﻀﺤﺔ ﺒﻌﺩ ﻤﺭﻭﺭ ﺍﻟ
ﺒﻌﺩ ﺍﻟﺤﻘﻥ ، ﺒﻌﺩ ﺫﻟﻙ ﺘﻡ ﺍﻟﺤﻘﻥ ﻜﺘﺎﻜﻴﺕ ﺘﺠﺎﺭﺏ ﺒﺤﺼﺎﺩ ﺍﻟﺯﺭﻉ ﺍﻟﺨﻠﻭﻱ ﺍﻟﺫﻱ ﻅﻬﺭ ﻋﻠﻴـﻪ 
vix 
  ﻤﺭﺽ ﻠﺘﻲ ﺘﺴﺒﺒﻬﺎ ﻓﻴﺭﻭﺱ ﺘﺠﻪ ﻋﻥ ﻅﻬﻭﺭ ﺃﻋﺭﺍﺽ ﻤﺭﻀﻴﺔ ﻤﻁﺎﺒﻘﺔ ﻟ ﺍﻷﺜﺭ ﺍﻟﻤﺭﻀﻲ ﻤﻤﺎ ﻨ 
ﻔﺱ ﻭﻋﺩﻡ ﺤﺭﻜﺔ ﺍﻟﻜﺘﺎﻜﻴﺕ ﺍﻟﻤﺼﺎﺒﺔ ﻭﻭﻀﻌﻬﺎ ﺍﻟﺠﺭﺍﺏ ﺍﻟﻤﻌﺩﻱ ﻓﻲ ﺍﻟﺩﻭﺍﺠﻥ ﻤﺜل ﺼﻌﻭﺒﺔ ﺍﻟﺘﻨ 
ﻟﻤﻨﻘﺎﺭﻫﺎ ﻋﻠﻲ ﺍﻷﺭﺽ ﻭﻤﻨﻅﺭ ﺍﻟﺭﻴﺵ ﻏﻴﺭ ﺍﻟﻤﺘﺴﻕ ﻤﻤﺎ ﻴﺩل ﻋﻠﻲ ﺍﻟﻤﺭﺽ ﺜﻡ ﺍﻟﻤﻭﺕ ، ﺒﻌﺩ 
ﻅﻬﻭﺭ ﻫﺫﻩ ﺍﻷﻋﺭﺍﺽ ﻭﺭﺼﺩﻫﺎ ﺜﻡ ﺍﺨﺫ ﻋﻴﻨﺎﺕ ﻟﻠﻔﺤﺹ ﺍﻟﻨـﺴﻴﺠﻲ ﺍﻅﻬـﺭ ﻓﻴﻬـﺎ ﺠـﺭﺍﺏ 
  .  ﻭﺫﻤﺔ  ﻓﻲ ﺤﻭﻴﺼﻼﺕ ﺍﻟﺠﺭﺍﺏ  ﻭﻓﺎﺒﺭﻴﺸﺹ ﻟﻠﻜﺘﺎﻜﻴﺕ ﻨﺯﻴﻑ
ﺩ ﻤﻊ ﺍﻻﻟﻭﻤﻨﻴﻭﻡ ﻫﻴﺩﺭﻭﻜـﺴﻴﺩ ﻜﻤـﺴﺎﻋﺩ  ﻟﻭﺼـﻭل ﻤﻬﻤﺭﻭﺱ ﺍﻟ  ﻤل ﻤﻥ ﺍﻟﻔﻴ 001ﺜﻡ ﺨﻠﻁ 
ﻭ ﻟﻠﻤﻘﺎﺭﻨﺔ ﺘﻡ ﺤﻘـﻥ ( ﺸﻤﺒﺎﺕ /60)ﺒﻌﺩ ﺫﻟﻙ ﺘﻡ ﺤﻘﻥ ﻜﺘﺎﻜﻴﺕ ﺍﻟﺘﺠﺎﺭﺏ ﺒﻭﺍﺴﻁﺔ  ، ﻴﻥﺍﻟﻔﺎﻜﺴ
ﻟﻡ ﺘﻅﻬﺭ ﺃﻱ ﻋﻼﻤﺎﺕ ﺃﻭ ﺃﻓﺎﺕ ﻤﺭﻀـﻴﺔ 87 D , 607ruB. ﻜﺘﺎﻜﻴﺕ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻔﺎﻜﺴﻴﻨﺎﺕ 
  . ﻨﺘﻴﺠﺔ ﻟﻠﺘﻠﻘﻴﺢ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻔﺎﻜﺴﻴﻥ ﺍﻟﻤﻌﻤﻠﻲ ﻤﻤﺎ ﻴﺩل ﻋﻠﻲ ﺴﻼﻤﺘﻪ 
 ﺒﺈﻀﺎﻓﺔ ﺍﻻﻟﻭﻤﻨﻴﻭﻡ ﻫﻴﺩﺭﻭﻜﺴﻴﺩ ﻜﻌﺎﻤل ﺎﺒﻁﺭﻴﻘﺎﻥ ﺍﺤﺩﻴﻬﻤ ( ﺸﻤﺒﺎﺕ /60)ﺇﻋﺩﺍﺩ ﺍﻟﻔﺎﻜﺴﻴﻥ ﺘﻡ 
ﻭﺜﻡ ﺤﻘﻥ ﺍﻟﻔﺎﻜﺴﻴﻥ ﺍﻟﻤﻌﻤﻠﻲ . ﻤﺴﺎﻋﺩ ﻭﻜﻤﻴﺔ ﺃﺨﺭﻱ ﻤﻥ ﻏﻴﺭ ﺇﻀﺎﻓﺔ ﺍﻻﻟﻭﻤﻨﻴﻭﻡ ﻫﻴﺩﺭﻭﻜﺴﻴﺩ 
ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻟﺤﻘﻥ ﺘﺤﺕ ﺍﻟﺠﻠﺩ ﻭﻓﻲ ﺍﻟﻌﻀل ، ﻭﻜﺎﻨﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻷﻓﻀل ﻤﻥ ﺤﻴﺙ ( ﺸﻤﺒﺎﺕ/60)
ﻓﻰ ﺍﻟﻤﺠﻤﻭﻋﻪ ﺍﻟﺘﻰ ﺘـﻡ ﺤﻘﻨﻬـﺎ ﻴﺔ ﻀﺩ ﺍﺨﺘﻴﺎﺭ ﺍﻟﺘﺤﺩﻱ ﻟﻠﻔﺎﻜﺴﻴﻥ ﺍﻻﺴﺘﺠﺎﺒﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻭﺍﻟﺤﻤﺎ 
ﺍﻟﻤﻀﺎﻓﺔ ﺇﻟﻴﻪ ﺍﻟﻌﺎﻤل ﺍﻟﻤﺴﺎﻋﺩ ﺍﻟﺫﻱ ﺃﻋﻁﻰ ﻋﻥ ( ﺸﻤﺒﺎﺕ / 60)ﺍﻟﻤﻌﻤﻠﻲ  ﺒﻭﺍﺴﻁﻪ ﺍﻟﻔﺎﻜﺴﻴﻥ 
ﺃﻭﻀﺤﺕ ﺍﻟﺘﺠﺭﺒﺔ ﺇﻥ ﺍﻟﻔﺭﻕ ﻓﻲ ﺍﻻﺴﺘﺠﺎﺒﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻋﻨﺩ ﺇﻀﺎﻓﺔ . ﻁﺭﻴﻕ  ﺍﻟﺤﻘﻥ ﻓﻲ ﺍﻟﻌﻀل 
ﻟﻠﻔﺎﻜﺴﻴﻥ ﺍﻟﻤـﻀﺎﻑ %  02ﺒﻨﺴﺒﺔ ﺍﻟﻌﺎﻤل ﺍﻟﻤﺴﺎﻋﺩ ﻭﻋﺩﻡ ﺇﻀﺎﻓﺘﻪ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﺤﻘﻥ ﺘﻜﻭﻥ 
  . ﺇﻟﻴﻪ ﺍﻟﻌﺎﻤل ﺍﻟﻤﺴﺎﻋﺩ ﻤﻤﺎ ﻴﻭﻀﺢ ﺃﻫﻤﻴﺔ ﺍﻟﻌﺎﻤل ﺍﻟﻤﺴﺎﻋﺩ ﻓﻲ ﺭﻓﻊ ﻨﺴﺒﺔ ﺍﻻﺴﺘﺠﺎﺒﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ 
vx 
  ﻤـﻊ 87D, 607 ruBﻤﻜﺎﻨﻴﺔ ﺍﻟﻤﻘﺎﺭﻨﺔ ﺒﻨﻲ ﺍﻟﻔﺎﻜﺴﻴﻨﺎﺕ ﺍﻟﺘﺠﺎﺭﻴﺔ ﺇﻜﺫﻟﻙ ﺍﻟﻨﺘﺎﺌﺞ ﺃﻭﻀﺤﺕ 
ﻀل ﻜﻤـﺎ ﺍﻟﻤﻀﺎﻑ ﺇﻟﻴﻪ ﺍﻟﻌﺎﻤل ﺍﻟﻤﺴﺎﻋﺩ ﻋﻨﺩ ﺤﻘﻨﻪ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻌ ( ﺸﻤﺒﺎﺕ /60)ﺍﻟﻔﺎﻜﺴﻴﻥ 
  87 D ﻭﺍل( ﺸـﻤﺒﺎﺕ /60)ﺎﺭ ﺍﻟﺘﺤﺩﻱ ﺒﻴﻥ ﻓﺎﻜﺴﻴﻥ ﺘﺒﺃﻅﻬﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ ﻭﺠﻭﺩ ﺘﺸﺎﺒﻪ ﻓﻲ ﺍﺨ
  .  ﺃﻅﻬﺭ ﺃﻓﻀﻠﻴﺔ ﺒﻨﺴﺒﺔ ﻀﺌﻴﻠﺔ ﻤﻥ ﺍﻟﻔﺎﻜﺴﻴﻨﻴﻥ ﺍﻟﺴﺒﺎﻗﻴﻥ 607 ruBﺒﻴﻨﻤﺎ ﻨﺠﺩ ﺇﻥ 
      ﺤﺘـﻰ         000,8) ﺍﻟﻌﺎﻟﻴﺔ ﺍﻟﻤﺤﺼﻭﺭﺓ ﺒﻴﻥ ﻋﻴﻪﺎﻥ ﻨﺴﺒﺔ ﺍﻻﻨﺴﺠﺎﻡ ﻓﻲ ﺍﻻﺴﺘﺠﺎﺒﺔ ﺍﻟﻤﻨ ﻜﻤﺎ ﻨﺠﺩ ﺇ 
( ﺸﻤﺒﺎﺕ/60 )ﺡ ﺃﻜﺜﺭ ﻋﺩﺩﺍ ﻭﺍﻨﺴﺠﺎﻤﺎ ﻓﻲ ﺍﻟﻁﻴﻭﺭ ﺍﻟﺘﻲ ﺘﻡ ﺤﻘﻨﻬﺎ ﺒﺎﻟﻠﻘﺎ ﺼﻭﺭﻩﺒﻅﻬﺭﺘ000,21
  .ﻓﻲ ﺍﻟﻌﻀل 
    ﻓﻲ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﺤﺎﻟﻴﺔ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻟﺘﻲ ﺃﻅﻬﺭﻫﺎ  ﺍﻟﻠﻘﺎﺡ ﺍﻟﻤﺤﻀﺭ ﻤﻥ ﺍﻟﻌﺘـﺭﻩ ﺃﻟﻤﺤﻠﻴـﻪ ﺒﻌـﺩ 
ﺍﻫﻤﺎﺩﻩ ﻴﻭﻋﺩ ﻭﻴﺅﺸﺭ ﺇﻟﻰ ﺍﺤﺘﻤﺎﻟﻴﻪ ﺇﻥ ﻴﻜﻭﻥ ﺍﻟﺨﻴﺎﺭ ﺍﻷﻓﻀل ﻟﻠﺘﻠﻘﻴﺢ ﻀـﺩ ﺍﻟﻤـﺭﺽ ﻓـﻲ 
  .  ﺍﻟﺴﻭﺩﺍﻥ 
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Introduction 
        Infectious bursa disease (IBD) an acute viral disease of young 
chickens was first described by Cosgrove (1962), characterized by 
destruction of the bursa of Fabricius followed by immunosuppressant 
(Allan, Faragher and Cullen, 1972, Fadley, Winterfield and Gander, 
1976).The disease was widespread in chickens and is of great 
economic importance for both broiler and pullet growers (Lukert and 
Saif, 1991). 
The virus genome consists of two segments of double strand 
RNA. Based on virus neutralization test (VNT) IBDV is classified 
into serotypes, serotype 1 and 2 (Jackwood, 1985). Serotype 1 viruses 
are pathogenic to chickens while serotype 2 viruses (isolated from 
turkeys) are non-pathogenic to chickens. 
Recently, the IBDV has become more virulent and the picture 
of the disease has changed and become more severe than in early 
outbreaks in 1980s. In the recent years IBD become the most 
devasting disease of chicken in the Sudan with mortality rates that 
exceed 60% even in vaccinated flocks, with the ability of the virus to 
change its genetic structure in order to survive a continual barrage of 
new vaccines. 
The vaccine may not contain the proper strains or serotypes of 
organism required to stimulate protective immunity against the field 
virus. Although the vaccine is administered properly and uniformly 
and adequate antibody titers are present, the chickens still break with 
the disease. 
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The objectives of this study are 
1. To isolate IBD field strain virus                                                           
2. To develop a vaccine by propagation and inactivation of the 
isolated virus. 
3. To compare the immune response of the developed inactivation 
local vaccine with   commercial vaccines (D78 and Bur706). 
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Chapter One 
Literature Review 
 
1.1. Infectious Bursal Disease 
1.1.1. Definition 
          Infectious bursal disease is an acute disease of young chickens 
of 3-6 weeks old, characterized by sever depression, ruffled feasther, 
whitish watery diarrhea, anorexia, depression, occasionally nephrosis, 
dehydration and death due to destruction of lymphoid cells in the 
bursal of fabricius and other lymphoid organs (Anon, 2000). 
1.1.2. History 
     IBD was discovered by Cosgrove in 1962, at that time it was 
called avian nephrosis because of the extreme kidney damage found 
in birds that succumbed to infection. The disease was first observed 
in Gumboro, Delware, USA by Cosgrove (1962) as a result the 
disease is often referred to as (Gumboro).Winterfield and Hitchner 
(1962) later isolated the causative virus and differentiated the IBD 
entity from the nephritis syndrome caused by certain infectious 
bronchitis variant viruses, the isolate was identified as infectious 
bursal disease (IBD), as the disease causes specific pathognomic 
lesions in the cloacal bursa. 
1.1.3. Economic importance 
      The economic impact of IBD is influenced by the strain of the 
virus, susceptibility of flocks, intercurrent primaey and secondary 
environmental and managemental factors, flock livability, weight 
gain, conversion and reproductive efficiency (Shane et al., 1994). 
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In addition to deaths, and immunosupperssion, losses from IBD 
including depressed growth rate, feed conversion efficiency are 
recorded in affected broiler flocks (Shane et al., 1994). 
Further more the increase use of antibiotics and chemicals to 
fight secondary infections is a major concern of human health, if we 
consider the risks linked to the presence or residues in meat products, 
the release of residues into environment and increased antibiotic 
resistance (Marian, 2001). 
Monitoring is vital studies that show economic impact of both 
clinical and subclinical IBDV infections can be significant. It is also 
too easy to underestimate the problem. Monitoring is an important 
tool to help to minimise the damage. Besides, the aforementioned 
reasons (a subclinical infection is a risk factor for a clinical outbreak 
in the next flock, and can cause immunosuppression, which may 
result in significant economic losses), monitoring also provides 
information about vaccine application. When vaccinated birds are still 
negative in IBDVserology at slaughter this is a strong indication that 
the vaccination protocol needs to be checked. It is better to carry out 
checks on a regular basis, rather than when there are complaints, 
because by then it is already too late (Sjaak, 2001). 
1.1.4. IBDV in Sudan 
    The first outbreak in the Sudan was observed at El Obied (North 
Kordofan state) in 1981with pronounced mortality (36%) (Shuaib et 
al., 1982).Since that time the disease has been reported in many parts 
of the Sudan and became a serious problem facing the poultry 
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industry in the Sudan (Hajer and Ismail, 1987). (Gaffer et al., 1987) 
found that Kassala State sera epidemic logically related virus strain to 
that of Elobied outbreak was reported. Then in Nyala in 1986 with 
50% mortality and another outbreaks in the same location with 45% 
mortality (Mansour et al., 1993) and since then it became endemic 
whenever massive poultry production is practiced in the country 
(Shuaib et al.,1982., Salman et al.,1983 and Mahasin1998).Although 
El Hussein et al.,(1998) observed some seasonal in northern Sudan. 
The recorded symptoms were likely confined to the exotic breeds 
(Hajer et al., 1988 and Mansour et al., 1993). However, surveys 
revealed presence of specific antibodies against IBD virus in local 
types of chickens yet they had not been vaccinated and seem 
apparently healthy (Elhassan et al., 1989) and Gaffar Elamin et al., 
1987). A mild form of the disease in broilers was reported by 
Khalafalla et al., (1990) 
            Incidence of sub clinical IBD infection in Sudan was 
evidently discussed by, Mahasin (1998). She attributed the 
vaccination failure-that is usually encountered-to these infections. 
                   Unfortunately, vaccination of birds irrespective to their 
status of immunity or the type of vaccine is usually practiced by 
many breeders (personal communication). Moreover, the highly 
variable IBD vaccines which including invasive strain were frankly 
used in routine vaccination programmer, despite that their use – in 
some countries-necessitate previous approval form the authorities 
Gardin (1994). 
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1.2. Aetiology 
1.2.1. Classification and structure 
        At the first time IBDV was classified as a picorna virus (Lunger 
and Madux 1972). Then as Reo virus (Petex and Mandelli, 1968; 
Koster et al., 1972).At last IBDV was regarded as a member of 
Birnaviridae family in the Avibirnavirus genus. Other genera in that 
family were Aquabirnavirus of pancreatic necrosis virus of fish 
(Murphy, Gibbis, Horzinekand Student 1999). The genome consists 
of two double stranded RNA segments designated as A and B (Miiler 
et al., 1979).The smaller genomic segment encodes viral protein 
(VP1) the viral polymerase (Azad, Barret and Fahey, 1985).The 
larger segment of the genome encodes three proteins VP2,VP3 and 
VP4, of which VP2 are structural proteins, also VP2 exists as 
precursor protein (VPx) and cleaved product,VP2 neutralizing 
monoclonal antibodies (Mab) have been shown to bind to VP2 
whereas VP3 does not carry neutralizing epitopes (Fahey et al.,1991 
and Snyder et al.,1992). The VP3 is regarded as a group specific 
antigen as it is recognized by monoclonal antibodies directed against 
VP3 from strains of both serotype 1 and 2 IBDV (Becht et al., 1988), 
while VP4 is viral protease (Fahey et al., 1991). VP4 and VP5 
respectively are responsible for the maturation of capsid proteins and 
for virus releases from the infected cell (Eterradossi, 2001).  
1.2.2. IBDV serotypes 
      Two serotypes of IBDV had been recognized known as serotype 
1and serotype 2 (Jack Wood, Saif and Huges, 1982, Mcferran et al., 
1980). The two serotypes are differentiated by virus neutralization 
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(VN) test (Lukert and Saif, 1991). Only serotype 1 viruses are 
pathogenic for chickens while serotype 2 is most prevalent in Turkeys 
(Ismail,Saif and Moorhead,1988), also serotype 2 strain neither cause 
disease nor protection against infection with the serotype 1 strains 
(Katizierenberg et al.,2004). The two serotypes share a common 
antigen demonstrated in agar gel precipitation test (Synder et al., 
1992). 
1.2.3. IBDV serotype 1 strains 
      The terms (variant),(classical),(very virulent) have been used to 
qualify the IBDV stains that exhibit a different pathogenicty.North 
American variants IBDVs include little if not clinical signs and no 
mortality but marked bursal lesion. Classical IBDVs induce 
approximately 10-50% mortality with typical signs and lesions where 
very virulent IBDVs induce approximately 50-100% mortality with 
typical signs and lesions (Eterradossi et al., 2001). 
  Jack Wood and Saif (1987) using (VN) test, detected significant 
antigenic differences among serotype 1 IBDV. They studied 8 
serotype 1 commercial vaccine strains, 5 serotype 1 field strain and 2 
serotype 2 field strains. Six subtypes were distinguished among the 
13 serotypes. One of the subtypes included all of the variant isolates 
(Saif et al., (1987).These subtype viruses are causing infection often 
before 2 weeks of age with no mortality but bursal atrophy (Vob and 
Vielitz, 1994). 
1.2.4. Very virulent (VV) IBDV strain 
      In 1987 a highly pathogenic strain (84VB) of type 1 IBDV 
emerged in Holland and Belgium (Van den Berg et al., 1991). 
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Mortality in layer replacement pullets attained 70% and 100% in 
experimental infection. These strains break through maternal 
antibodies, which were protective against classical strains (Chettle et 
al., 1989, Vob and Vielitz, 1994).Within few years, this highly 
pathogenic IBDV strain spread over Europe, Middle East, South 
Africa and South East Asia (Vob and Vielitz, 1994). In the Sudan the 
highly virulent strains were detected within the viruses isolated since 
1994(onwards, Mahasin, 2001). 
1.3. Pathology of IBD 
1.3.1. Susceptible age 
      Clinical IBD is most commonly recognized in susceptible 3-6 
weeks old birds, chickens younger than 3 weeks have subclinical 
infection (Lukert and Saif., 1991). 
Light layer breeds have been reported to be more susceptible than 
heavy broilers (Van den Berg and Meulemans., 1991). 
1.3.2. Transmission of IBDV 
       IBD is excreted in the feces of infected birds for 2-14 days; it is 
highly contagious and transmission occurs directly through contact 
and oral uptake (Murphy et al., 1999). IBD is stable at pH 3 to pH 9 
and can survive 60ºC for 60 minute (Murphy et al., 1999). Due to the 
hardy nature of the virus it persists in the environment of the poultry 
house. Infections are thus potentially carried over from one cycle to 
the next. It can be transmitted from infected hens to others by 
contaminated tools, equipment, feed or water, boots or clothes of 
labors and all people who move from farm to other. The Aedes vexans 
mosquitos and meal worms (Alphitobius diaperinus), have been 
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incriminated as even more important vectors (Howie and Thorsen, 
1981, Snedeker, Wills and Moulthrop, 1967). IBDV was 
demonstrated in tissue sample of rat’s coats dead in a house that has a 
history of IBDV (Lasher and Shane., 1994). Vertical transmission 
probably occurs via eggs (Murphy et al., 1999).Torents et al (2004) 
have studied the possibility of transmission of IBDV by dogs. A 
single Beagle dog feed chicks infected by very virulent strain of IBD 
.After-ward the presence and the viability of IBDV was detected in 
dog feces for 2 days after initial ingestion. Techniques of the 
administered and excreted IBDV show similar characters between the 
two viruses (Torents et al., 2004). 
1.3.3. Pathogencity of IBDV 
       The target organ of the IBDV is the bursa of Fabricius which is 
specific reservoir of B lymphocyte in avian species. Bursectomy can 
prevent illness in chicks infected with virulent virus (Hiragar et al., 
1994; Murphy et al., 1999).The severity of the disease is directly 
related to the number of susceptible cells present in the bursa of 
Fabricius.Therefore the highest age of susceptibility is between 3-6 
weeks, when the bursa of Fabbricius at its maximum development. 
After oral infection or inhalation, the virus replicates primary in the 
lymphocyte and macrophage of gut associated tissue. Then virus 
travels to the bursa via blood stream, where replication occurs .By 13 
hours most follicles are positive for virus and by 16 hours post 
infection, a second and pronounced viraemia occurs in other organ 
leading to disease and death (Miiller et al., 1979). No disease occur 
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after 15-16 weeks of age when the bursa is regressed (Sainsbury, 
2003) 
The terms variant, classical, very virulent, have been used to qualify 
the IBDV strains that exhibit a different pathogenicty. 
1.3.4. Histopathology 
       The spleen had hyperplasia of reticuloendothelial cells around the 
adenoid sheath in arteries in early stages of infection. By the third day 
there was lymphoid necrosis in the germinal follicles and peri 
arteriolar lymphoid sheath. The spleen recovered from infection 
rather rapidly, with no sustained damage to germinal (Lucent and 
Saif, 1991). The thymus and caecal tonsils exhibited some cellular 
reaction in the lymphoid tissues in early stages of infection, but as in 
the spleen the damage was less extensive than in bursa and recovery 
was more rapid. Harderian gland was severely affected by infection 
of one –day old chicks with IBDV, which results in reduced 
infiltration of plasma cells (Dohms, and Rosenberger, 1981). 
Histological lesions of the kidney are non-specific (Peters, 1967), and 
probably occur because of sever dehydration of affected chickens. 
Helmboldt and Garner (1964) found kidney lesions in less than 5% of 
birds examined. Lesions observed were large casts of homogeneous 
material infiltrated with heterophils. 
1.3.5. Morbidity and Mortality 
         Morbidity and mortality depend on the virulence of the 
challenged virus, the immune status and age of the infected birds and 
other factors affecting the pathogenicity of IBDV in full susceptible 
flocks, there is high morbidity rate usually approaching 100% (Lukert 
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and Saif, 1991). Classical mortality ranges from zero to 30 % (Lukert 
and Saif, 1991), but very virulent IBDVs strains can cause mortality 
of 70%-80% (Chettle et al., 1989, Murphy et al., 1999). 
1.4. Immunosuppression 
       The term immunosuppression is defined as a state of temporary 
or permanent dysfunction of the immune response resulting from 
insult to the immune system and leading to increased susceptibility to 
disease (Dohms and Saif, 1983). IBD immunosuppression first 
recognized by Allan, Faragher and Cullen (1972) and Faragher et al 
(1974). It is due to market depletion of lymphocytes in the lymphoid 
organs (Nakamura et al., (1992). Immunosuppression resulting from 
IBD infection, weakness response to vaccination and makes chickens 
more susceptible to a number of other infections diseases (Anon, 
2000). 
       The main target cells for IBDV replication are the activity 
dividing B cell; thus infection leads to the destruction of B cells in the 
bursa of Fabricius, the primary organ of B cell development, and to 
lesser degrees in other organs such as the caecal tonsils, and spleen. 
The destructive effect of IBDV on B cells leads to a dramatic 
reduction in the ability of the IBD infected bird to produce antibodies 
against antigens, in addition to reducing humeral immunity. IBDV 
also leads to suppression of the cell mediated immune response, also 
suppression of macrophage function (Rautens Chlein .2001). 
1.5. Diagnosis of IBD 
Diagnosis of IBD in chickens is historically based on clinical 
signs, gross lesions, and histopathology. Confirmation of the 
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diagnoses is based on detection of viral antigen, detection of 
antibodies and isolation of the virus (Liiticken, Vanloon and Devries, 
1994). 
1.5.1. Isolation of IBDV in chick embryo 
        The chorioallantoic membrane (CAM) of 9-10 day old embryo 
was the most sensitive route for isolation of the virus (Hitchner, 
1970).Injection of the virus into 10-day old embryonated eggs 
resulted in embryo mortality from 3-5 days past inoculation. 
According to Winterfield, (1969) the virus increased in 
allantoumniotic fluid by serial passage in embryonating eggs, while 
Okoge (1984) mentioned that serial transfer of IBDV in chick embryo 
may reduce virulence for chickens. The recent very virulent strains 
are difficult to cultivate in embryonated eggs (Bumstead et al., 1993). 
1.5.2. Isolation of the virus in chickens 
       This method has been used in the past but is no longer 
recommended due to animal welfare concerns. Five susceptible and 
five IBD-immune chickens (3–7 weeks of age) are inoculated by the 
eye drop route with 0.05 ml of sample. The bursa of chickens infected 
with virulent serotype 1 IBDV appears yellowish (sometimes 
hemorrhagic) and turgid, with prominent striations. Peribursal 
oedema is sometimes present, and plugs of caseous material are 
occasionally found. The presence of lesions in the bursa of 
susceptible chickens along with the absence of lesions in immune 
chickens is diagnostic of IBD. The bursa from both groups may be 
used as antigen in an agar gel immunodiffusion (AGID) test against 
known positive IBD antiserum. The extent of bursal damage may 
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vary considerably with the pathogenicity of the studied IBDV strain. 
However, as the samples submitted for virus isolation may vary in 
virus content, the extent of bursal damage observed in susceptible 
chickens at the isolation stage gives a limited indication on strain 
pathogenicity. The bursa of chickens infected with serotype 2 IBDV 
does not exhibit any gross lesions. 
1.5.3. Isolation of the IBDV in cell culture 
     Many strains of IBDV have been adapted to cell cultures of 
chicken embryo origin and cytopathic effect has been observed. Cell 
culture adapted virus may be quantified by plaque assay (Lukert and 
Saif, 1991).The virulent IBDV are very difficult to adapt to tissue 
culture and when adapted became less virulent (Mekkes and Deuite, 
1994). IBDV grows in chicken embryo fibroblast and produces (CPE) 
characterized with and appearance of round retractile cells in   about  
3-5 days (Sivanadan et al.,1993).The old strains or classical strain of 
IBDV can be isolated in chicken embryo kidney (CEK) (Lukert and 
Davis,1974), also mammalian continuous cell lines known to be 
susceptible to IBDV ( RK-13) derived from rabbit kidneys 
(Peter,Daprile and Cancellotti, 1973),Vero cells derived from African 
green monkey kidneys (Jack Wood et al.,1987), and MA-104 cell 
from fetal monkey kidneys (Jack Wood et al.,1987). Wild type IBDV 
strains particularly very virulent strain do not grow in tissue culture. 
Comparison of genome sequence of wild type and tissue culture 
adapted IBDV strains pointed to several mutations that might be 
responsible for invitro growth of IBDV in tissue culture (Islam, 
2002). When the replication of IBDV in Vero cells and chicken 
 14
embryo kidney cells was compared no differences in virus titres were 
observed (Leonard, 1974). However, the replication cycle was found 
to be longer in Vero cells than in CEF cells (Lukert et al., 1975). 
1.5.4. Plaque production 
      Plaque formation of IBDV growth in cell culture was reported 
(cho et al., 1979) in two shape small plaque (SP) and large plaque 
(LP) variants were obtained from IBDV adapted to chick embryo cell 
culture (Saijo, Higashihara, Fujisaki and Matumoto, 1990). 
1.6. Identification of the agent 
      Clinical IBD has clearly characteristic signs and post-mortem 
lesions. A flock will show very high morbidity with severe depression 
in most birds lasting for 5–7 days. Mortality rises sharply for 2 days 
then declines rapidly over the next 2–3 days. Usually between 5% 
and 10% of birds die, but mortality can reach 30–40%. The main 
clinical signs are watery diarrhea, ruffled feathers, reluctance to 
move, anorexia, trembling and prostration. Post-mortem lesions 
include dehydration of the muscles with numerous ecchymotic 
hemorrhages, enlargement and orange discoloration of the kidneys, 
with urates in the tubules. The bursae of Fabricius show the main 
diagnostic lesions. In birds that die at the peak of the disease 
outbreak, the bursa is enlarged and turgid with a pale yellow 
discoloration. Intrafollicular hemorrhages may be present and, in 
some cases, the bursa may be completely hemorrhagic giving the 
appearance of a black cherry. Peribursal straw-coloured oedema will 
be present in many bursas. Confirmation of clinical disease or 
detection of subclinical disease is best done by using immunological 
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methods as the IBDV is difficult to isolate. Differentiation between 
serotypes 1 and 2 or between serotype 1 subtypes or pathotypes 
should be undertaken by a specialized laboratory (OIE, 2004). 
1.6.1. Sample preparation 
Remove the bursa of Fabricius aseptically from approximately 
five affected chickens in the early stages of the disease. Chop the 
bursa using two scalpels, add a small amount of peptone broth 
containing penicillin and streptomycin (1000 µg/ml each), and 
homogenize in a tissue blender. The homogenate should be 
centrifuged at 3000 g for 10 minutes and the supernatant fluid was 
collected in sterile vials for use in the virus investigations. Filtration 
through a 0.22 µl filter may prove necessary to further control 
bacterial contamination, although this may cause a reduction in virus 
titer (OIE, 2004). 
1.6.2. Identification by the agar gel immunodiffusion test 
The AGID is the most useful of serological test for detection of 
specific antibodies in serum or for detecting viral antigen in bursal 
tissue (OIE, 2004).The test is specific because it can not give false 
positive results, but it can give a false negative result. The presence of 
IBDV antigen can be detected in the bursal tissue by AGID for 5-6 
days Pi (Murphy et al., 1999). 
1.6.3. Virus Neutralization Test (VNT) 
VNT is carried out in cell culture. The test is more laborious 
and expensive than the AGID, but is more sensitive for detecting 
antibody. The sensitivity is not required for routine diagnostic 
purpose, but may be useful for evaluation vaccine responses or for 
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differentiation between IBDV 1 and 2 serotypes (OIE, 2004). It is 
difficult to use VNT in recent vvIBDV strains, because they are 
difficult to cultivate in cell culture. 
1.6.4. Identification by antigen-capture enzyme-linked 
immunosorbent assay (AC-ELISA). 
Different protocols have been described for the detection of 
serotype 1 IBDV using an antigen-capture enzyme-linked 
immunosorbent assay (AC-ELISA). Briefly, ELISA plates are coated 
with IBDV-specific antibodies. Depending on the chosen AC-ELISA 
protocol, the capture antibody may be a mouse anti-IBDV 
monoclonal antibody (MAb), or a mix of such MAbs, or a chicken 
post-infectious anti-IBDV polyclonal serum. Unbound antigens are 
discarded at the end of the incubation period by washing with a 
suitable washing buffer. The captured antigens are then revealed, as 
in an indirect ELISA, with a detection antibody, followed by an 
enzyme conjugate that binds to the detection antibody only, followed 
by the enzyme substrate. Finally, optical densities, which parallel the 
amount of captured IBDV antigens, are read with an ELISA reader 
(Marquardtt et al., 1980)  
1.6.5.    Identification by molecular techniques 
Molecular virological techniques have been developed that 
allow IBDV to be identified more quickly than by virus isolation. The 
most frequently used molecular method is the detection of IBDV 
genome by the reverse-transcription polymerase chain reaction (RT-
PCR). This method can detect the genome of IBDV, which is unable 
to grow in cell culture, because it is not necessary to grow the virus 
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before amplification. RT-PCR is performed in three steps: extraction 
of nucleic acids from the studied sample, reverse transcription (RT) 
of IBDV RNA into cDNA, and amplification of the resulting cDNA 
by PCR. The two latter steps require that the user selects 
oligonucleotide primers that are short sequences complementary to 
the virus-specific nucleotidic sequence. Different areas of the genome 
can be amplified depending on the location from which the primers 
have been selected.  
1.7. Vaccines 
      The term ‘vaccine’ is used for products containing live or 
inactivated viruses or protozoa, live bacteria, or nucleic acids. 
Products containing killed bacteria and other microorganisms are 
identified as bacterins, bacterial extracts, subunits, bacterintoxoids, or 
toxoids, depending on the type of antigen they contain, products 
administered to animals in order to produce active or passive 
immunity or to diagnose the state of immunity’, however, the term 
‘vaccine’ will include all products designed to stimulate active 
immunization of animals against disease 
1.7.1. Vaccine type 
1.7.1.1. Live vaccine 
     Live IBD vaccines are produced from fully or partially attenuated 
strains of virus, known as ‘mild’, ‘intermediate’, or ‘intermediate 
plus’ (‘hot’), respectively. Mild or intermediate vaccines are used in 
parent chickens to produce a primary response prior to vaccination 
near to point-of-lay using inactivated vaccine. They are susceptible to 
the effect of MDA so should be administered only after all MDA has 
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waned. Application is by means of intramuscular injection, spray or 
in the drinking water, usually at 8 weeks of age (Skeeles et al., 1979). 
Intermediate or intermediate plus vaccines are used to protect broiler 
chickens and commercial layer replacements. Some of these vaccines 
are also used in young parent chickens if there is a high risk of natural 
infection with virulent IBD. Although intermediate vaccines are 
susceptible to the presence of MDA, they are sometimes administered 
at 1-day old, as a coarse spray, to protect any chickens in the flock 
that may have no or only minimal levels of MDA (Mazariegos et al., 
1990). This also establishes a reservoir of vaccine virus within the 
flock that allows lateral transmission to other chickens when their 
MDA decays. Second and third applications are usually administered, 
especially when there is a high risk of exposure to virulent forms of 
the disease or when the vaccinated chicks exhibit uneven MDA levels 
(Kouwenhoven, et al., 1994). The timing of additional applications 
will depend on the antibody titers of the parent birds at the time the 
eggs were laid. As a guide, the second dose is usually given at 10–14 
days of age when about 10% of the flock is susceptible to IBD and 
the third dose 7–10 days later. Live IBD vaccines are generally 
regarded as compatible with other avian vaccines. However, it is 
possible that IBD vaccines that cause bursal damage could interfere 
with the response to other vaccines (OIE, 2004). 
1.7.1.2. Inactivated vaccine 
           Inactivated IBD vaccines are used to produce high, long-
lasting and uniform levels of antibodies in breeding hens that have 
previously been primed by live vaccine or by natural exposure to field 
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virus during rearing (Cullen and Wyeth, 1975). The usual programme 
is to administer the live vaccine at about 8 weeks of age. This is 
followed by the inactivated vaccine at 16–20 weeks of age. The 
inactivated vaccine is manufactured as a water-in-oil emulsion, and 
has to be injected into each bird. The preferred routes are 
intramuscular into the leg muscle, avoiding proximity to joints, 
tendons or major blood vessels or the subcutaneous route. A 
multidose syringe may be used. Used in this way the vaccine should 
produce such a good antibody response that chickens hatched from 
those parents will have passive protection against IBD for up to about 
30 days of age (Wyeth and Cullen, 1979). This covers the period of 
greatest susceptibility to the disease and prevents bursal damage at 
the time when this could cause immunosuppression. 
1.7.1.3. In Ovo vaccine 
        Recently, technology has been developed to deliver live vaccine 
into eggs during the incubation period. Live vaccine virus is blended 
with IBD antibody and the complex is injected in ovo at 18 days of 
incubation. The eggs go on to hatch and the vaccine virus is released 
when the chicks are about 7 days of age. In this way, the problem of 
maternally derived IBD antibody is overcome and the chicks are 
effectively immunized (Haddad et al., 1997). 
1.7.1.4. Recombinant vaccines 
     The concept of recombinant vaccines is to insert genes of critical 
immunizing epitopes of a disease agent into nonessential gene of a 
vector virus. Vaccination with the recombinant virus thus results in 
immunization against both the vector virus as well as the expressed 
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epitopes of the disease agent (Hung et al., 2004) have developed a 
recombinant Newcastle disease virus (NDV) expressing VP2 protein 
of IBDV that protect against both NDV and IBD.      
1.8. Vaccine manufacture 
The vaccine must be manufactured in suitable clean and secure 
accommodation, well separated from diagnostic facilities or 
commercial poultry. Production of the vaccine should be on a seed-lot 
system using a suitable strain of virus of known origin and passage 
history. Specific progeny free (SPF) eggs must be used for all 
materials employed in propagation and testing of the vaccine. Live 
vaccines are made by growth in eggs or cell cultures. Inactivated IBD 
vaccines may be made using virulent virus grown in the bursae of 
young birds, or using attenuated, laboratory-adapted strains of IBDV 
grown in cell culture or embryonated eggs. A high virus 
concentration is required. These vaccines are made as water-in-oil 
emulsions. A typical formulation is to use 80% mineral oil to 20% 
suspension of bursal material in water, with suitable emulsifying 
agents. (FAO). 
1.9. Advantages and Disadvantages of live vaccines                                                  
      Advantages of live-type vaccines are ease of administration, low 
price, rapid onset of immunity, and a broader scope of protection 
because chickens are exposed to all stages of the replicating virus. 
Disadvantages include problems with uniform vaccine application, 
excessive vaccine reactions, unwanted spread of the vaccine virus to 
neighboring poultry houses, and extreme handling requirements 
needed to maintain viability of the vaccine organism. 
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1.10. Advantages and Disadvantages of killed vaccines                                             
      Advantages of killed-type vaccines are assurance of 
administration of a uniform dose (birds are individually injected), 
safety (the organism has been inactivated), development of uniform 
levels of immunity (each bird receives the same dose), no chance for 
spread of vaccine organism to neighboring poultry farms, increased 
product stability, and a choice of a wider variety of virus strains. 
Disadvantages are increased costs (labor and product), slower onset 
of immunity, narrower spectrum of protection, and presence of 
localized tissue damage at site of injection due to reaction with the 
adjuvant. 
1.11. Vaccination 
      Selecting a vaccination program for broilers and commercial 
layers involves the following considerations: 
1. Size and scope of the operation. Operation of single or multiple-
age facilities.     
2. Standard of biosecurity. Density of poultry population in the area. 
3. Pathogenicity of IBD viruses to which flocks may be exposed. 
4. Availability of live attenuated (intermediate-plus or "hot") and 
inactivated vaccines 
Source of chicks, whether from company-operated parent flocks or 
from purchased commercial eggs or chicks. (OIE, 2004). 
1.12. Administration 
      The route of administration is by means of spray or in the 
drinking water. Intramuscular injection is used rarely. If the vaccine 
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is given in the drinking water, clean water with a neutral pH must be 
used that is free from smell or taste of chlorine or metals. Skimmed 
milk powder may be added at a rate of 2 g per liter. Care must be 
taken to ensure that all birds receive their dose of vaccine. To this 
end, all water should be removed (cut off) for 2–3 hours before the 
medicated water is made available and care must be taken that no 
residual water remains in the water adduction pipes or in the drinkers. 
It is possible to divide the medicated water into two parts, giving the 
second part 30 minutes after the first. (OIE, 2004) 
1.13. Vaccine Failure 
         Multiplication of live vaccines, reducing the amount of 
immunity produced. For example, if a chick comes from a breeder 
hen with high levels of antibody against Gumboro, the chick will 
typically have high levels of antibodies. A high level of maternal 
antibodies in the young chicken may interfere with the (maternal) for 
several weeks if vaccination is attempted in the presence of these 
antibodies (Van den Berg et at., 1991). 
Stress may reduce the chicken's ability to mount an immune response. 
Stress could include environmental extremes (temperature, relative 
humidity), inadequate nutrition, parasitism, and other diseases. 
Chickens should not be vaccinated during periods of stress. That is, 
delay vaccination until the birds are healthy. 
      Live vaccines may be inactivated due to improper handling or 
administration. Before administering live vaccines, check and record 
lot numbers and expiration dates on the vials. Store and handle 
vaccines as recommended by the manufacturer the vaccine may not 
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contain the proper strains or serotypes of organism required to 
stimulate protective immunity. Although the vaccine is administered 
properly and uniform and adequate antibody titers are present, the 
chickens still break with the disease, particularly with infectious 
bronchitis and more recently with infectious bursal disease. 
       Poor distribution of live vaccine administered by the water or 
spray route may result in chickens being "missed" in parts of the 
house (Relying on transmission of the vaccine from bird to bird is 
risky, and can result in excessive rolling-type reactions of long 
duration and delayed immunity in the flock (Farmer,1992). "Misses" 
with killed vaccines will result in chickens with no protection, as 
killed vaccines will not spread from bird to bird. 
    Chickens may already be incubating the disease at the time of 
vaccine administration. Despite proper administration, the birds 
become diseased because time is needed for antibody production to 
begin and reach protective levels. Remember, after first exposure to a 
live virus-type vaccine, immunoglobulin's G, M, and are first detected 
approximately 4 to 5 days following exposure. Additional days are 
required for titers to reatch protective levels. 
1.14. IBDV control 
            The control of IBDV strains involves many factors ,such as 
disinfection,vaccination programs and understanding the 
epidemiology of the IBDV.IBDV like all viruses have  known 
treatment ,also IBDV have high stability in the environment, 
therefore IBDV can persist in poultry houses  after cleaning and 
disinfection. The principle method to control the disease is therefore 
 24
by vaccination (Van Denberg and Meulemans, 1991). High levels of 
biosecurity should be enforced with specific reference to movement 
of personnel, feed and vehicles. On-farm trading and prolonged 
depletion periods will result in the introduction and persistence of 
vvIBD infection. It is essential to operate farms on an all-in-all-out 
cycle and to maintain an acceptable distance between units to prevent 
cross transmission of vvIBDV. 
It is necessary to maintain high and uniform levels of protective 
maternal antibody in commercial chicks. This is achieved by effective 
priming and boosting the immune system of parent flocks placed on 
isolated farms. Vaccination programs should incorporate successive 
intermediate strain vaccines or in extreme risk situations, 
intermediate-plus vaccine followed by subsequent administration of 
inactivated bursal-derived emulsion vaccines. 
Maternal antibody levels should be monitored using an ELISA or 
quantitative agar gel procedure to measure the efficacy of the 
vaccination program (Gardin, 1994). Broiler chicks, under extreme 
risk, should be vaccinated with intermediate-plus ("hot") vaccine. If 
this unobtainable, an intermediate vaccine can be used in combination 
with an inactivated oil-emulsion product. Although costly in terms of 
labor and vaccine, this approach has proven effective for small units. 
Procedures relating to storage, reconstitution and administration of 
vaccines should be rigorously controlled. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1. Preparation and sterilization 
2.1.1. Preparation and sterilization of glassware 
 Glassware's like flasks, beakers and measuring cylinders were rinsed 
in running tap water, brushed with special tissue culture flask soap, 
and left overnight in 1% HCl. Washed thoroughly by rinsing several 
times in tap and distilled water. After that they were wrapped with 
aluminum foil and sterilized in hot air oven at 160oC for 1 hour. The 
volumetric pipettes were left overnight in 3% HCl. Then they washed 
thoroughly by rising several times in tape and distilled water. The 
clean dry pipettes were cotton plugged, placed in canisters and 
sterilized in hot air oven at 160oC for 1 hour.  
2.1.2. Preparation and sterilization of plastic wares 
 Rubber liners for bottles and plastic cylinders were cleaned with 
detergent, washed with tap water followed by distilled water, left to 
dry and sterilized by autoclaving at 121oC (15b/squire inch) for 15 
minutes. 
2.1.3. Preparation and sterilization of filters and filter papers 
 Millipore filter papers (0.22 µ) were assembled in their appropriate 
holders, wrapped in aluminum foil and sterilized by autoclaving at 
121oC (151b/squire inch) for 15 minutes.  
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2.2. Chicks 
  All chicks used in the present study (n=155) were kindly supplied 
by Coral Hatcheries, Khartoum.  
Chicks were obtained as day-old and reared till the required age. 
2.3. Embryonated eggs 
 These were obtained from a white leghorn parent flock (Bovans 
breed). This flock is kept under strict hygienic measures at the 
premises of the Microbiology Department. Faculty of Veterinary 
Medicine, University of Khartoum. 
 2.4. IBD Strains    
           Two vaccines commercially available were selected for the 
study; 
 a- D78 inter mediate vaccine strain produced by intervet, Boxmear-
Holland. Each does contain at least 4.0 log10 TCID50 of the Gomboro 
strain D78 plus stabilizers and antibiotics. Its application for 
vaccination is either by drinking water, spray and intranasal / intra-
ocular routes. 
 b- Bur706 a modified live vaccine against IBDV produced by Merial 
Italia spa, Italy. Strain s706 has at least 104 TCID50 plus stabilizers 
and antibiotics. Its application for vaccination is either by drinking 
water, spray and intranasal / intra-ocular routes. 
C-Sudan local field isolate after inactivation.  
2.5 IBD Challenge Virus 
           The live local field isolated in the work was used as the 
challenge virus.  
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2.6. Hyperimmuno serum 
             Three pair of rabbit was inoculated subcutaneonsly with D78 
vaccine as IBDV antigen then after two weeks rabbit were given a 
double dose and another double does after three weeks and three 
weeks post last does blood was collected from the rabbit heart, in 
sterile test tubes. The blood was left for 2 hours at room temperature 
then the clot was loosened from the surface of the tubes and kept 
overnight at 4oC. Then the serum was separated and clarified by 
centrifugation at 2000 rpm for 10 minutes. The serum antibody was 
tested against IBDV antigen in AGPT. 
2.7. The AGPT 
2.7.1. Preparation of agar for AGPT: 
 On a glass container 1.4 g purified agar was added to 100 ml agar 
buffer (Appendix n=10) mixed and put in a steamer for an hour and 
then dispensed in Petri dishes in 17 ml volume per dish. The agar was 
solidified by air at room temperature. After solidification 7 holes 
were made, 6 outer and one inner. The 7 holes make a shape of circle. 
The diameter of each hole was 6 mm with 3 mm interspaces between 
holes.  
2.7.2. Test procedure 
 Using a pipette 20 µL of 10% bursal or spleen homogenates were 
put in one of the 6 around wells and 20 µL of the hyperimmune 
serum was put in the inner well. Then the gel was incubated in a 
humidified chamber at room temperature for 24 – 48 hours 
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2.8. Chick embryo cell culture 
2.8.1. Tissue culture preparation 
        To prepare chick embryo fibroblast monolayer ten-day-old 
embryonated eggs were used.  
Procedure 
  Embryonated eggs were obtained from the poultry farm of Virology 
Research laboratory, Department of Microbiology, Faculty of 
Veterinary Medicine, University of Khartoum. Eggs were incubated 
till 9-11day old .The incubated eggs were candled for viability and 
then the shell surfaces were cleaned by immersing in 70% alcohol for 
5 minutes. The round shell just below air sac was cut by pairs of 
scissors, and the embryo was collected by placing the scissors under 
its head and the embryo lifted out. 
The head and the limbs of the embryo were cut, viscera were 
removed and remains were fragmented with scissors into small 
fragments. 
        Then the fragments were washed several times with phosphate 
diluents (PD) (Appendix n=2) and transferred to a trypsinization 
flask. 
       The trypsinization was carried out with discontinuous manner. 
5ml of prewarmed trypsin versin solution (Appendix n=5) per 
embryo were added and stirred slowly for 15 minutes at 37ﮦC. After 
the tissue had settled out, the supernatant cells (containing single cells 
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and small cluster of cells) were collected in container with one to two 
ml of calf serum (Appendix n=6) and kept on ice. This was repeated 
3-4 times until only the white fibrous tissues were left and no more 
cells dispense. Then the supernatant containing the pelleted cells were 
resuspended by the equation of each 1 cubic centimeter cells to 100ml 
of growth media and mixed by pipetting. Then the diluted suspension 
was distributed into 50 ml flask, 7.5 ml/flask and in 6 well plates (2 
ml/well) and then incubated at 37ﮦC. Confluent monolayers were 
established within 2-3 days.  
2.9. ELISA for antibodies detection  
        Description of the Test   
                The IBD ELISA kit used was manufactured by BioChek, 
Gouda, Holland.  The test kit was used according to the manufacturer 
instructions.Microtitre plates have been pre-coated with inactivated 
IBD antigen. Chicks’ serum samples are diluted and added to the 
microtitre wells where any anti-IBD antibodies present will bind and 
form an antigen –antibody complex. Non specific antibodies and 
other serum protein are then washed away. Anti-chicks IgG labeled 
with the enzyme alkaline phosphatase is then added to the wells and 
binds to any chicks anti –IBD antibodies bound to the antigen. After 
another wash to remove unrelated conjugate, substrate was added in 
the form of PNPP chromogen. A yellow colour is developed if anti-
IBD antibody is present and the intensity is directly related to the 
amount of anti-IBD present in the sample. 
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2.9.1. Reagents provided 
1. IBD Coated plates. Inactivated viral antigen on microtitre plates. 
2. Conjugate reagent Anti-chicks: Alkaline Phosphatase in tris 
buffer with protein stabilizers, inter red dye and sodium azide 
preservative (0.1%w/v). 
3. Substrate tablets. PNPP (p-Nitrophenyl Phosphate) tablets to 
dissolve with Substrate buffer. 
4. Substrate buffer reagent.Diethanolamine buffer with enzyme co-
factors. 
5. Stop solution. Sodium Hydroxide in Diethanolamine buffer. 
6. Sample diluent reagent. Phosphate buffer with protein stabilizers 
and sodium azide preservative (0.1%w/v). 
7. Wash buffer. Powdered Phosphate buffer Saline with tween. 
8. Negative control .Specific Pathogen Free serum in Phosphate 
buffer with protein stabilizers and sodium azide preservative 
(0.1%w/v) 
9. Positive control. Antibodies specific to IBD in Phosphate buffer 
with protein stabilizers and sodium azide preservative (0.1%w/v) 
2.9.2. Test procedure 
1. IBD coated plate was removed from sealed bag and recorded 
location of samples on template. 
2. 100µl of negative of negative control was added into wells A1 and 
B1. 
3. 100µl of positive control was added into wells C1 and D1.  
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4.100µl of diluted samples was added into the appropriated wells. 
Plate was covered with lid and incubated at room temperature for 30 
minutes. 
5. Wells contents were aspirated and washed 5 times with wash 
buffer (300µl per well). Plate inverted and tap firmly on absorbent 
paper. 
6. 100µl of Conjugate reagent into the appropriated wells. Plate was 
covered lid and incubated at room temperature.  
7. Wash was repeated as in step 5 procedure. 
8.100µl of Substrate reagent was added into the appropriated wells. 
Plate covered with lid and incubated at room temperature for 15 
minutes. 
9. 100µl of Stop solution was added to appropriate wells to stoped the 
reaction. 
10. Then the microtitre plate was read at 405nm using an ELISA 
reader (Sun Raise) reader. 
2.9.3. Interpretation of results 
Samples with a sample to positive ratio (S/P) of 0.2 or greater contain 
anti-IBD antibodies and are considered positive. 
Calculation of S/P ratio: 
     Mean of Test Sample-Mean of negative control                  = S/P  
   Mean of positive control- Mean of negative control  
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Calculation of Antibody Titre 
The Following equation relates the S/P at a 1:500 dilution to an end 
point titre. 
Log (S/P)+3.361.٭ Log10 Titer =1.1 
Antilog=Titer  
S/P value                             Titre Range                    Antibody 
status 
0.149 Or less                         284 or less                            Negative  
0.150-0.199                           285-390                                Suspect 
0.200or greater                      391 or greater                        Positive 
2.10. Inactivated Vaccine development 
Virus isolation 2.10.1.  
2.10.1.1Infectious bursa disease virus field isolate 
 Isolation of IBDV field isolate 
     IBDV-field strain was isolated from an outbreak, which occurred 
at Shambat in Khartoum State in August 2006. The affected layer 
birds were 7 weeks old. The main clinical signs were depression, 
ruffled feathers, watery diarrhea. Morbidity and mortality rates were 
100% and 90% respectively. Gross lesions were dehydrated 
carcasses; hemorrhage in thigh and pectoral muscles and at the 
junction between proventriculus and gizzard. Bursa of Fabriciuus was 
edematous, enlarged and some of them were hemorrhagic 
2.10.1.2. Collection of tissue specimens  
      Postmortem examination was performed and bursa and spleen 
were removed aseptically from infected chickens into sterile bottles 
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and immediately transported in ice to the laboratory where the 
specimens stored at -20◦C until used. 
2.10.1.3. Preparation of tissue homogenate 
     The bursa were cut into small fragments using two scissors, and 
small amount of normal saline containing 1000 units /ml penicillin 
was added to make 40% homogenate by grinding the tissue fragment 
with a pestle and mortar. The homogenate was clarified by 
centrifugation at 3000 rpm for 10 minutes in a bench centrifuge. The 
supernatant was harvested, stored at – 20◦c in sterile bijous and 
labeled.  
2.10.2. Identification of IBDV antigen  
2.10.2.1. By the AGPT. 
Procedure of the test  
 Using a pipette, the test antigen was dispensed into the 6 outer wells 
while dispensing the hyperimmuno serum in the center one. The gel 
was then incubated in a humidified chamber at room temperature for 
48 hours.  
2.10.2.2. By virus isolation in chick embryo fibroblast 
         The bursal and spleen homogenates were inoculated onto chick 
embryo fibroblast. Each 25ml small cell culture flask received 0.5ml 
of the inoculums. The cell culture flasks were incubated at 37◦c for 1 
hour after which the inoculum was removed and the cell sheet washed 
with PD (Appendix n=2) three times. Maintenance media (Appendex 
n=12) was added and the flasks were incubated at 37◦c.The flasks 
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were daily examined by an inverted microscope to check for 
cytopathic effect (CPE).      
2.10.2.3. By experimental infection  
   A number of 15 six weeks old chicks were inoculated orally with the 
1ml of the tissue homogenate. Additional group of 5 birds were left as 
uninfected control. The infected chicks were observed daily for 
clinical signs and the morbidity and mortality recorded. Postmortem 
examination was performed on recently dead chicks and specimens 
(bursa) for histopathology were taken.       
2.10.3. Virus propagation and adaptation 
     Tissue homogenates were inoculated onto confluent chick embryo 
cell culture prepared in 25 cm3 tissue culture flask. Each flask 
received 0.5 ml of the inoculum and left for 1 hour at 37˚C for 
absorption. Then the inoculum was removed and the confluent 
monolayer were washed twice with PD (Appendix n=2) and refer 
with maintenance medium (GMEM) (Appendix n=12) and kept at 
37˚C.  The cell culture was examined daily microscopically for the 
present of cytopathic effect (CPE). All the flasks that show CPE were 
harvested by repeated freeze-thaw cycles, and the suspension is 
clarified by low-speed centrifugation (1500 rpm for 10 minutes) .The 
supernatant fluid was harvested. 
2.10.4. Titration of IBDV Field Isolate in cell Culture 
 Ten fold serial dilutions 10-1 to 10-10of the pooled IBDV 
field isolate harvests were prepared and used in titration procedure. 
CEF prepared in 96 wells microtiter plates were inoculated with the 
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diluted virus volume 0.1ml, each virus dilution was inoculated in five 
wells and at last five wells were left as controls and incubated for 
absorption for one hour then media was added. Daily investigation for 
cytopathic effect was done and the last reading was taken at the 5th 
day. The titer was calculated according to the method of Reed and 
Muench (1938). 
2.10.5. Inactivation   
       Inactivation of the vaccine virus and any potential contaminants 
in the harvested virus was achieved by treatments with formalin. 
(Formaldehyde solution (37-41% w/v HCHO) LOBA CHEMIE PVT 
LTD Mumbai, India). The formalin was in concentration of 0.2 %( 
v/v) (Habib et al., 2006) in a conical flask that contained a stirring 
bar. The mixture was stirred continuously and the inactivation was 
continued for 48 hours at room temperature.The inactivated vaccine 
was inoculated into 3- weeks old susceptible chicks at the rate of 
0.3ml/bird subcutaneously (Helmboldtt and Garner, 1964). Birds 
were observed for 5 day post inoculation. 
2.10.6. Addition of adjuvant to the inactivated virus 
              Aluminum hydroxid (Rona CareTm Merck KgaA/ 64271 
Darmstadt, Germany) was used as an adjuvant with the persentege 
5%.  
2.11. Experimental Vaccination Trials 
          A number of 140 layer chickens were divided into 7 groups of 
20 chicks each. 
      Group1: Vaccinated with D78 in the drinking water according to 
the manufacturer instructions  
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      Group2: Vaccinated with Bur706 in the drinking water according 
to the manufacturer instructions   
      Group3: Vaccinated with the developed inactivation IBD vaccine 
Shambat/o4/adj. Each bird received 0.5 ml inoculated in the thigh 
muscle with 1ml disposable syringe and needle.  
      Group4: Vaccinated with the developed inactivation IBD vaccine 
Shambat/o4/. Each bird received 0.5 ml inoculated in the thigh 
muscle with 1ml disposable syringe and needle.  
      Group5: Vaccinated with the developed inactivation IBD vaccine 
Shambat/o4/adj. Each bird received 0.5 ml inoculated sub cut with 
1ml disposable syringe and needle.  
      Group6: Vaccinated with the developed inactivation IBD vaccine 
Shambat/o4. Each bird received 0.5 ml inoculated sub cut with 1ml 
disposable syringe and needle.  
       Group 7: unvaccinated control birds. 
       At day six of age a number of 25 sera were collected and 
examined by ELISA for antibodies against IBD to determine the best 
day of vaccination in which the maternal antibody allows. The first 
dose of vaccination was given at 17 days old acourding to the result. 
Anther booster dose was given 10 days after the first dose for both 
developed inactivated vaccine and the two commercials vaccine 
(D78and Bur706). Five weeks later sera were collected and tested for 
immune response by ELISA.  
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2.12. Challenge  
                All birds in the 7 groups were challenged with the local 
isolate of IBDV at the age of 5 weeks. Each bird received a dose 
volume of 0.5ml by the orally route that contained 105.2 TCID50/ml. 
The challenge virus was isolated in CEF and given at the second 
passage. 
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Chapter Three  
Results 
 
3.1. Detection of infectious bursal disease virus antigen in bursal 
tissues collected from field specimens 
3.1.1. AGPT results 
     IBDV was identified in the 40% bursal homogenates. The 
sample gave precipitin line with the known antiserum against IBDV 
indicating the presence of IBDV antigen in the bursal homogenate 
(Fig.2). 
3.1.2. Isolation of IBDV in CEF cell culture 
            The field isolate virus after tested with AGPT was inoculated 
onto chicken embryo fibroblast (CEF) cell culture. No cytopathic 
effect (CPE) was seen in the four days post inoculation. At the 5th day  
clear rounded cells were observed and the cells start to detach from 
the flask surface within 24 hours making small sized  plaques 
distributed  in different parts of the monolayer (Figures 1 and 2). 
3.1.3. Titration of field isolate in CEF cell culture 
        The field isolate pool harvest (Shambat/06) gave a titer 5.2 log10 
TCID50/0.1ml.   
3.1.4. Experimental infection with IBDV field isolate. 
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A number of 15 chicks were inoculated with the bursal 
homogenate.  
3.1.4.1. Clinical Signs  
Typical clinical signs of IBD were observed at day 5 pi.The 
affected birds showed dullness, ruffled feather reluctant to move, 
recumbence with the beak on the earth off food and pasted vent. 
Mortality rate was 100%, at the same time no clinical signs were 
observed at the control group.    
3.1.4.2 Postmortem findings  
Experimental infected chicks showed dehydration of carcose, 
hemorrhages in skeletal muscles (thigh) (Figures 6, 7). In some cases 
there were hemorrhages in the junction of proventriculus and gizzard 
(Figure 8). Bursa of fabriciues enlarged (2-3 times) and became 
edematous, yellowish and in few birds hemorrhagic. No postmortem 
changes were observed in the control group        
3.1.4.3 Histopathological lesions 
   The bursa of Fabricius of infected chickens showed and infiltration 
of mononuclear cells which consisted of lymphocytes. The lymphoid 
follicles showed degeneration. Hemorrhages, edema was occasionally 
observed in the connective tissues and between the dissociated 
follicular cells. 
3.2. Inactivation result 
          The expermantal chicks showed neither sign nor lesion after 
inoculated with the inactivated vaccine.  
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The inactivated vaccine was inoculated into 3- weeks old susceptible 
chicks at the rate of 0.3ml/bird subcutaneously. Birds were observed 
for 5 day post inoculation (Helmboldtt and Garner, 1964). 
 
3.3. Results of Immunity test    
     Antibody titer was detected by ELISA in sera of chicken 
vaccinated by both the commercials (D78 and Bur706) and the 
inactivated vaccine (Shambat/06). 
   For Bur706, D78 and Shambat/06 which administrated I/M and S/C 
with adjuvant or with out, table (1) express the comparative between 
them for the immune response and the challenge and the Figures from 
8 to 13 expressed the group's immune results. 
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Figure 1.Wet preparation of uninfected chick embryo fibroblast cell 
culture 3 days after culturing   
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Figure1-2.Wet preparation of fibroblast cell culture field infected 
after inoculated with field IBDV isolate shambat/06 at day 5th shown 
cytopathic effect of cell rounding 
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 Figure 2. Identification of IBDV by AGDT. Wells 1-4, 40% bursa 
homogenate. Well 5 control negative (Normal saline) well 6 control 
positive (Known IBDV antigen).   
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Figure 3-1 postmortem changes in chicks experimentally inoculated 
with bursa homogenate at day 6 pi .Arrow point to hemorrhage at the 
thigh muscles 6 days pi (arrow). 
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Figure 2-2 .Postmortem changes in chicks experimentally inoculated 
with bursa homogenate at day 6 pi .Arrows shown hemorrhage in 
thigh muscles 6 days pi (arrow).  
 
 
  
  
  
  
 
 
 
 
Figure 4.Proventriclus and gizzard collected at day 6 pi chicks 
inoculated with bursa homogenate. Arrow points to hemorrhages in 
the mucosa at the junction of the proventriculus and gizzard (arrow). 
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 Figure 5. Section of bursa of fabricious collected from chicks 
experimentally inoculated with 40%bursa homogenate IBDV.Note; 
hemorrhage in the connective tissues and between the dissociated 
follicular cells (arrow). 
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Figure 6. Section of bursa of fabricious collected from chicks 
experimentally inoculated with 40%bursa homogenate IBDV. Note, 
edema in the follicle of bursal of fibricius (arrow).  
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Figure 7. Section of bursa of fabricious collected from chicks 
experimentally inoculated with 40%bursa homogenate IBDV. Note, 
degeneration of follicles (arrow). 
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Table 1: Immune response and challenge of chicks vaccinated 
against IBD with 6 vaccination regimes.  
  
  
Control Sh/06   
S/C 
Sh/06/adj  
S/C 
D78 
During 
water 
Bur706 
During  
water 
 
Sh/06  
I/M 
Sh/06/adj 
I/M 
  
0/20= 0 5/15 
=33.3% 
 
7/15 
=46.7% 
14/15=9
3.3% 
14/15=93.3
%   
11/15=7
3.3% 
14/15 = 
 93.3% 
ProtectiveImmu
ne  response 
0/20    = 
0 
7/20        
=35% 
 
9/20= 
45% 
 
15/20 
=75% 
16/20b 
=80% 
13/20  = 
65% 
15/20 
 = 75% 
With standing    
challenge   
 
  
 Sh= Shambat 
Adj= adjuvant 
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Table 2: Distribution of positive ab level of chicks sera 
collected after vaccinated with Shambat/o6 with and without 
adjuvant, D78and Bur706. 
     
  
 
Bur706 
vaccinated 
chicks number 
D78 vaccinated 
chicks number 
Shambat/06/noadj 
number of chicks 
(I/M)   
Shambat/06/adj 
number of chicks 
(I/M)   
Ab range 
- - - - 1000 
4 5 7 3 2000-4000 
4 2 2 2 4000-6000 
4 - 3 3 6000-8000 
2 6 3 7 8000-10000 
1 2 - 1 10000-12000 
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Figure 8. Distribution of antibody titers groups in sera of chick's 
antibody titer group detected by ELISA after vaccinated using 
D78 . 
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Figure 9. Distribution of antibody titer groups in sera of chicks 
detected by ELISA after vaccinated using Bur 706 orally.  
 
 
0
1
2
3
4
5
0 2000 4000 6000 8000 10000 12000
  
  
  
  
0=Negative results   
  
  
 
 
Titer group 
Se
ra
sa
m
pl
es
 53
 
Figure 10.Distribution of antibody titers groups in sera of chicks 
detected by ELISA after vaccinated by Shambat/06 with out 
adjuvant S/C. 
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Figure 11. Distribution of antibody titers groups in sera of 
chicks detected by ELISA after vaccinated by Shambat/06 with 
adjuvant S/C. 
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Figure 12. Distribution of antibody titers groups in sera of 
chicks detected by ELISA after vaccinated by shambat/06 no 
adjuvant I/M.  
0
1
2
3
4
5
6
7
8
0 2000 4000 6000 8000 10000
 
 
 
 
0=Negative results 
 
 
 
 
Titer group 
Se
ra
 sa
m
pl
es
 
 56
 
  
Figure13. Distribution of antibody titers groups in sera of chicks 
detected by ELISA after vaccinated by shambat/06/adj  I/M.  
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CHAPTER FOUR  
DISCUSSION 
 
        The infectious bursal disease virus was first known in the Sudan 
as a health problem since 1980, yet the first published field report of 
the disease dated back to 1982 (Shuaib et al., 1982). The virus has 
since been implicated in many economic losses in different parts of 
the country. In addition, the increase use of antibiotics to fight 
opportunistic (secondary) infection is a major concern to human 
health, if we consider the risk linked to the presence or residues in 
meat. In Sudan outbreaks of the disease cause high mortality rate 
despite vaccination.This may denotes to a vaccination failure which 
might be due to emergence of a vvIBDV that is antigenically different 
from the virus in the vaccines used (Snyder, 1990).The vvIBD strains 
could establish infection in the presence of high level of maternal 
antibodies that were protective against classical strains as indicated 
by Chettle et al (1989) and cause up to 60%-100% mortality (Van den 
Berg et al., 1991). 
                In the present study an inactivated IBD vaccine were 
developed from a local field isolate of the virus. It is anticipated that 
the field virus would induce better immune response in vaccinated 
birds due to its close antigenic relation ship. A field outbreak of the 
disease that occurred in 2006 in Khartoum state (Shambat) was 
investigated that caused 70% mortality even in vaccinated bird. IBDV 
was detected by AGID test, isolation in cell culture (CEF) and 
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reproduction of the disease in experimental chicks. The virus was 
isolated in CEF cell culture and identified serologically by AGDT. 
The virus was designed Shambat/06 and further propagated for two 
passages in cell culture and the TCID50was determined. Then the CEF 
cell culture harvest was inactivated using formalin and the 
inactivation tested used experimental chicks. 
      A total of 140 layer chicks were used to determine the efficancy   
and safety of the developed vaccine and to compare it with 
commercial IBDV vaccines D78, Bur706.  
           The results showed that when the bursa suspension was 
inoculated onto chick embryo fibroblast cell culture it induce clear 
cytopathic effects after 5 days of inoculation. Clinical signs observed 
after experimental infection of susceptible   chicks were similar to the 
classical IBD clinical signs and were characterized by sudden onset 
of depression, dullness, ruffled featherand death. Theses signs are 
similar to those described in the early outbreaks of IBD by Cosgrove 
(1962) and also to those described by Parkhurst (1964). Tissues 
collected from experimental chickens were examined 
histopathologically. Bursal of fabricius showed hemorrhage in the 
connective tissues and the dissociated follicular cells beside edema in 
the follicle and degeneration of follicles.These findings agree with 
that of Okoye (1983), Lang et al (1987) and Lasher Shane (1994).  
     A volume of 100 ml of the inactivated virus was mixed with 
Aluminum hydroxide as adjuvant. Experimental chicks were 
vaccinated by the inactivated vaccine and for comparison additional 
chicks were vaccinated with D78and Bur706 commercial IBD 
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vaccines. No signs or lesions of IBD were seen and vaccinated chicks 
remained healthy throughout the experiment, which means that the 
IBDV in the vaccine was completely inactivated by the formalin.  
           Two preparations were made for the vaccine, with and without 
Aluminum hydroxide adjuvant and two routes of vaccination; 
intramuscular (I/M) and subcutaneous (S/C) were tried. The best 
result in terms of immune response and withstanding challenge was 
obtained when the adjuvanted inactivated vaccine was given by the 
intramuscular route. Results showed also that the developed vaccine 
without adjuvant when given by I/M gave a relatively lower 
protective immune response of 73.3% comparing with 93.3% for the 
adjuvanted vaccine which mean that the absent of the adjuvant make 
loss of 20% at immune response. 
      The results also revealed similar protective immune 
response for D78, Bur706 vaccine with the developed adjuvanted 
vaccine when given by I/M route. On the other hand, the developed 
vaccine without adjuvant when given by I/M showed 20% lower 
protective immune response compared with the commercial vaccines. 
The results also showed similler withstanding challenge for both 
shambat/06/adj and D78 while Bur706 was slightly better than both 
above vaccines. The higher uniformed higher titer from 8,000 upto 
12,000 was induced in vaccinated chicks by the developed vaccine 
with adjuvant when given by I/M.   
  The efficacy of the developed vaccine observed in the present 
study is promising and indicate that the developed vaccine may 
became a good alternative method to control IBD in Sudan. Similarly 
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Hossain et al (2004) found that a local field isolate of infectious 
bursal disease virus in Bangladesh can induce higher immune 
response in chickens than that of the commercially available IBDV 
vaccines.The authors explained the reason as due to degradation of 
the quality of the imported vaccines during transportation or in a new 
environmental condition or due to antigenic dissimilarities among the 
local field virus and the imported vaccines.  
       To control IBD by vaccination farmers use live or inactivated 
vaccine despite the field situation and which vaccine is better at the 
particular time. 
              Advantages of killed-type vaccines are assurance of 
administration of a uniform dose (birds are individually injected), 
safety (the organism has been inactivated), development of uniform 
levels of immunity (each bird receives the same dose), no chance for 
spread of vaccine organism to neighboring poultry farms, increased 
product stability, and a choice of a wider variety of virus strains. 
Disadvantages are increased costs (labor and product), slower onset 
of immunity, narrower spectrum of protection, and presence of 
localized tissue damage at site of injection due to reaction with the 
adjuvant. 
     Further research is needed to study the properties of the local 
isolates of IBDV using molecular techniques.There is also a need 
to determine immune response of the developed inactivated 
vaccine in parent stocks for the protection of offspring chicks in 
broilers. Trials of inactivation using binary ethylenimine are also 
needed to compare the inactivation and immune response with that 
of formalin. 
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CONCLUSION 
        
       1- It is possible to isolate and propagate or produce local IBDV 
isolate in CEF cell culture, for diagnosis and vaccine production. 
        2- The developed inactivated vaccine induced good immune 
response and withstanding challenge comparable to two 
commercially available vaccines (D78, Bur706).  
        3-The Aluminum hydroxide as adjuvant increased remarkabl 
immune response of chicks vaccinated with the inactivated IBD 
significantly. 
        4-The developed inactivated IBD with adjuvant vaccine 
administered I/M gave the highest numbers of protected birds and 
uniform antibody titer that ranged from 8,000 to 12,000, while the 
commercial vaccines gave less uniform antibody titer.  
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RECOMMENDATION 
   
1- CEF Cell culture is recommended to be method of 
identification, isolation and propagation of IBD samples from 
the field. 
2- Further research is needed to determine immune response of 
the developed inactivated vaccine in parent stocks for the 
protection of offspring chicks in broiler chicks. 
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APPENDEX 
 Reagents and solution  
 1-Normal saline (NS): 
      Stock solution of 0.85 %( w/v) NaCl was prepared in DDW and 
autoclaved at 121C for 20 minutes. 
 Phosphate buffer saline (PBS). 
Solution A: 
NaCl                                                  16gm 
KCl                                                   0.4gm 
Na2HPo4                                                                                2.3gm 
KHPo4                                                              0.4gm 
Complete to 1500 ml by DDW 
Solution B: 
   Hydrous MgCl26H2o             0.426gm 
Or 
   Anhydrous MgCl2               0.2gm 
Complete to 200 by DDW 
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Solution C:  
 CaCl anhydrous                         0.2gm 
Or 
CaCl2H2o hydrous                                         0.264gm 
Complete to 200ml 
               Each solution was autoclaved separately and solution A and 
B were added to C, then was completed to 2litres by adding sterile 
DDW. 
2- Preparation of phosphate diluents (PD):   
           Solution A of PBS was completed to 2liters with DDW; it was 
then autoclaved and cooled before antibiotic were added. 
3-Preparation of Stock Trypsin (2.5%): 
                2.5 grams of trypsin (Gibcol td UK 1:250 Usp Grade) were 
dissolving in 100ml of PD, filtered through What Man filter and 
stored at -20 ﮦC. 
4-Preparation of Stock Version (5%): 
                    5 grams of versin powder was dissolved in 100ml PD, 
autoclaved at 121◦C for 15 minutes.                                                                               
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5-Preparation of Trypsin Versin solution: 
          6ml of trypsin (2.5%) was added to 4ml of version (5%), 
completed to 100ml with phosphate diluents, with addition of few 
drops of phenol red were added pH adjusted by NaOH. 
6-Bovine serum: 
                  Calves were bled from the jugular vein. The whole blood 
was left overnight at room temperate serum was centrifuged at 2000 
rpm for 10 minutes, and then filtered through Seitz filter under 
negative pressure, tested for sterility using thioglycolate media and 
kept at-20◦C. 
7-Preparation of antibiotic solutions: 
                    One gram of streptomycin powder and the contents of 2 
vails of penicillin (1000000 IU/ vail) were dissolved in 10ml of sterile 
DDW so that 1ml of the prepared solution contained 100mg 
streptomycin and 2000000IU penicillin. The solution was kept at -
20◦C.  
8-Mycostatin: 
        One vail of Mycostation (50000ug) was dissolved in ten ml of 
sterile DDW so that 1ml of the solution contained 5000ug. 
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9-Preparation of Thioglycolate medium: 
            Twenty nine and half gram of thioglycolate medium was 
dissolving and dispensed in bijoux bottle. The medium was 
sterilization by autoclaving at 121◦C for 10 minutes.    
10-Preparation of 500 ml buffer for IBD AGPT 
Nacl                                                              40.0gm 
Phenol                                                           2.5gm 
DD.w make to                                               5oo ml 
Ph was adjusted to 7.5 by adding 1ml to 3ml NaoH solution 
11- Preparation and sterilization of media and solutions: 
          To prepare the five fold stock solution, 125.19gm of Glasgow 
Modified Eagles Medium (GMEM) powder were dissolved in two 
liters of deionized distilled water (final volume). The solution was 
filtered through Millipore filter (o.22 u) under positive pressure, 
tested for sterility using thioglycolate medium and stored at -200C.  
12- Growth and Maintenance media: 
         GMEM X 5 concentration                           200ml 
          0.5% lactalbumin hydrolysate                      25ml 
           1% yeast extracts                                       25ml 
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            Tryptose phosphate broth                           25ml  
            7.5%NaHco3                                              8ml  
           Penicillin / streptomycin                                1ml 
            Fungizone                                                   1ml 
DDW was added to complete to one liter. For preparation of growth 
media 100 ml of calf serum were added, 50 ml for maintenance.                                   
  
  
  
  
 
